Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States

• Type of Material: Article
• Authors: Chadi Nabhan, University of Chicago; Xiaolei Zhou, RTI Health Solutions; Bann-Mo Day, Genen - tech Inc; Keith Dawson, Genen - tech Inc; Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center; Jonathan W. Friedberg, University of Rochester; James R. Cerhan, Mayo Clinic; Brian K. Link, University of Iowa; Christopher Flowers, Emory University
• Language: English
• Date: 2016-08-01
• Publisher: Wiley
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2016 Wiley Periodicals, Inc.
• Final Published Version (URL): http://dx.doi.org/10.1002/ajh.24401
• Title of Journal or Parent Work: American Journal of Hematology
• ISSN: 0361-8609
• Volume: 91
• Issue: 8
• Start Page: 770
• End Page: 775
• Grant/Funding Information: This study was funded by Genentech Inc., South San Francisco, CA/F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Third-party editorial assistance, under the direction of the authors, was provided by Gardiner-Caldwell Communications and funded by Genentech Inc./F. Hoffmann-La Roche Ltd.
• Keywords: 1ST-LINE TREATMENT; Science & Technology; RITUXIMAB; SURVIVAL; INDOLENT; Hematology; RETROSPECTIVE ANALYSIS; PROGNOSIS; Life Sciences & Biomedicine; REGISTRY; GENDER; MULTICENTER; TRIAL
• Research Categories: Health Sciences, Public Health; Health Sciences, Oncology

Abstract

We aimed to comprehensively study sex differences in disease and patients' characteristics, treatment and outcomes in patients with follicular lymphoma (FL) in the United States (USA) utilizing the National LymphoCare Study registry (2004–2014). Among evaluable males (n = 1277) and females (n = 1375) with FL, females less commonly received anthracyclines and were more likely to receive rituximab monotherapy. Overall response rates were comparable between sex groups. With a median follow-up of 8.1 years, male sex emerged as an adverse factor for PFS (HR, 0.84, 95% CI, 0.72–0.97). Lymphoma-related mortality (HR, 0.46; 0.23–0.93) and overall survival (HR, 0.63; 0.41–0.97) favored females aged ≤60 years. There are subtle differences in outcomes between male and female FL patients diagnosed and treated in the contemporary era. These data represent the largest prospective analysis of FL patients in the USA based on sex and can aid design of clinical trials for this disease. Am. J. Hematol. 91:770–775, 2016. © 2016 Wiley Periodicals, Inc.